IMRX Earnings Date: Mar 11, 2027 (Estimated) — Immuneering Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is IMRX's next earnings date?
Immuneering Corporation (IMRX) is expected to report Q4 2026 earnings on Thursday, March 11, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.33.
How did IMRX do in its last earnings report?
In its most recent report on Oct 29, 2026, Immuneering Corporation posted EPS of -$0.37 versus the -$0.30 estimate, a miss of 21.3%.
How much does IMRX stock move after earnings?
IMRX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 5.5% (up or down) in the day after earnings.
About Immuneering Corporation
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
🤖 AI Earnings Analysis
Extended survival follow-up in atebimetinib combination-treated pancreatic cancer patients is encouraging, with updated Phase 2 data due; however, the $0.37 loss missed estimates by $0.08, keeping clinical validation pivotal.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | -0.30 | -0.37 | -21.30% | — | ❌ Miss | — | — | — | |
| 2026-08-05 | Q2 2026 | -0.26 | -0.27 | +0.00% | $0 | ❌ Miss | -0.23% | +9.09% | +14.09% |
| 2026-05-15 | Q1 2026 | -0.26 | -0.21 | +19.23% | $0 | ✅ Beat | +0.39% | +1.56% | -18.48% |
| 2026-03-06 | Q4 2025 | -0.31 | -0.18 | +41.94% | $0 | ✅ Beat | +7.03% | +9.44% | +8.43% |
| 2025-11-12 | Q3 2025 | -0.38 | -0.38 | +0.00% | $0 | ➖ Inline | -2.57% | +8.31% | -8.16% |
| 2025-08-13 | Q2 2025 | -0.40 | -0.40 | +0.00% | $0 | ➖ Inline | -5.59% | +6.52% | +163.66% |
| 2025-03-20 | Q4 2024 | -0.47 | -0.58 | -23.40% | $0 | ❌ Miss | +9.09% | +0.61% | -16.36% |
| 2024-11-13 | Q3 2024 | -0.55 | -0.49 | +10.91% | $0 | ✅ Beat | +13.45% | +19.30% | -4.39% |
Showing last 8 quarters.